Back to top
more

Annovis Bio (ANVS)

(Real Time Quote from BATS)

$7.66 USD

7.66
16,657

-0.03 (-0.39%)

Updated Aug 12, 2024 09:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro

Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.

Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody

Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.

Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion

Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.

Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study

Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.

Apellis (APLS) Provides Syfovre Q3 Preliminary Revenues Guidance

Apellis' (APLS) shares rise as it provides third-quarter 2023 preliminary revenues guidance for Syfovre, approved for the treatment of geographic atrophy.

Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin

Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction value of approximately $478 million. Shares rise 97%.

ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data

Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies

Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.

Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine

Per the terms of the deal, Sanofi (SNY) and J&J will co-fund current and future R&D costs to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli.

Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH

Apellis (APLS) receives the FDA approval for Empaveli Injector, a self-administred on-body device, to treat patients with paroxysmal nocturnal hemoglobinuria.

NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.

Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studies support the FDA filing.

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.

Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies

Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.

Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal

Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.

Repligen (RGEN) to Acquire Fluid Management Company Metenova

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).

Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study

Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.

Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.

Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.

Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.